Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Academic Article uri icon

Overview

abstract

  • Combined radiotherapy and gene therapy is a novel therapeutic approach for prostate cancer. There are various potential benefits in combining ionizing radiation with gene therapy to achieve enhanced antitumor effects: A) ionizing radiation improves transfection/ transduction efficiency, transgene integration, and possibly, the "bystander effect" of gene therapy; B) gene therapy, on the other hand, may interfere with repair of radiation-induced DNA damage and increase DNA susceptibility to radiation damage in cancer cells, and C) radiotherapy and gene therapy target at different parts of the cell cycle. Preclinical data have demonstrated the enhanced antitumor effects of this combined approach in local tumor control, prolongation of survival, as well as systemic control. This combined radio-gene therapy is under study in an ongoing clinical trial in prostate cancer. Our study adds gene therapy to the standard of care therapy (radiotherapy). These treatment modalities have different toxicity profiles. The goal of this combined approach is to enhance cancer cure without an increase in treatment-related toxicity. This approach also offers a new paradigm in spatial cooperation, whereby two local therapies are combined to elicit both local and systemic effects. Early clinical results showed the safety of this approach.

authors

  • Teh, Bin
  • Aguilar-Cordova, Estuardo
  • Vlachaki, Maria T
  • Aguilar, Laura
  • Mai, Wei-Yuan
  • Caillouet, James
  • Davis, Maria
  • Miles, Brian
  • Kadmon, Dov
  • Ayala, Gustavo
  • Lu, Hsin H
  • Chiu, J Kam
  • Carpenter, L Steven
  • Woo, Shiao Y
  • Grant, Walter H
  • Wheeler, Thomas
  • Thompson, Timothy C
  • Butler, Edward

publication date

  • January 1, 2002

Research

keywords

  • Genetic Therapy
  • Prostatic Neoplasms
  • Simplexvirus

Identity

Scopus Document Identifier

  • 18644363002

Digital Object Identifier (DOI)

  • 10.1634/theoncologist.7-5-458

PubMed ID

  • 12401909

Additional Document Info

volume

  • 7

issue

  • 5